Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2470-2473

  Matteelli, Alberto ^a   Villani, Paola ^b   Carvalho, Anna Cristina C ^a   El Hamad, Issa ^a   Cusato, Maria ^b   Apostoli, Alessandra ^a   Marcantoni, Claudio ^a   Calabresi, Alessandra ^a   Dal zoppo, Sarah ^a   Bigoni, Sara ^a   Regazzi, Mario ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antiretroviral therapy; Drug interactions; Treatment

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RIFABUTIN;

ADULT; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PLASMA; RIFABUTIN; RITONAVIR; TUBERCULOSIS;

EID: 84866622613     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks218     Document Type: Article

References (11)

1. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 Revision. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (2 March 2012, date last accessed).
2. van Waterschoot RA, ter Heine R, Wagenaar E et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 2010; 160: 1224-33.
3. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63: 769-802.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (2 March 2012, date last accessed).
5. Moyer TP, Temesgen Z, Enger R et al. Drug monitoring of antiretroviral therapy in HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999; 45: 1465-76.
6. van der Leur MR, Burger DM, la Porte CJ et al.A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit 2006; 28: 650-3.
7. Boulanger C, Hollender E, Farrell K et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-11.
8. Khachi H, O'Connell R, Ladenheim D et al. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009; 64: 871-3.
9. Boffito M, Arnaudo I, Raiteri R et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16: 2081-3.
10. Breilh D, Pellegrin I, Rouzés A et al.Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18: 1305-10.
11. La Porte CJL, Back DJ, Blaschke T et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3: 4-14.